New combo may let esophageal cancer patients keep their esophagus
NCT ID NCT06869226
First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 23 times
Summary
This study tests whether combining the immunotherapy drug camrelizumab with chemotherapy can shrink esophageal cancer enough to avoid surgery and preserve the organ. About 283 adults with resectable esophageal squamous cell cancer will receive the treatment before any surgery decision. The goal is to see if this approach can control the disease and improve survival without needing to remove the esophagus.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking University Cancer Hospital
RECRUITINGBeijing, 100142, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.